180 Life Sciences Corp. Files S-1/A Amendment

TL;DR

180 Life Sciences Corp. (fka KBL Merger Corp. IV) filed an S-1/A amendment on 12/20/24. Update on their public offering registration.

AI Summary

180 Life Sciences Corp. filed an S-1/A amendment on December 20, 2024, for its registration statement (No. 333-283265). The company, formerly known as KBL Merger Corp. IV until November 15, 2016, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA 94306.

Why It Matters

This filing indicates an update to the company's registration statement, which is a crucial step for companies planning to offer securities to the public or make significant changes to their existing public offerings.

Risk Assessment

Risk Level: medium — S-1/A filings often relate to significant corporate actions like public offerings or restructurings, which inherently carry market and execution risks.

Key Numbers

• 333-283265 — SEC File Number (Identifies the specific registration statement being amended.)
• 20241220 — Filing Date (Date the amendment was submitted to the SEC.)

Key Players & Entities

• 180 Life Sciences Corp. (company) — Registrant
• KBL MERGER CORP. IV (company) — Former company name
• December 20, 2024 (date) — Filing date
• 333-283265 (registration_number) — SEC file number
• Blair Jordan (person) — Interim Chief Executive Officer

FAQ

Key Financial Figures

• $0.0001 — 8 shares of our common stock, par value $0.0001 per share, of 180 Life Sciences Corp.,
• $1.50 — are exercisable at an exercise price of $1.50. We are not selling any common stock un
• $2,850,207 — receive proceeds of up to approximately $2,850,207. We intend to use those proceeds, if an
• $1.94 — common stock as reported on Nasdaq was $1.94 per share. INVESTING IN OUR SECURITIE
• $25,000 — quirements of the parties, subject to a $25,000 deductible. The closing of the transa
• $97 billion — ine gaming sector is estimated to reach $97 billion in 2024, and is projected to grow to ne
• $133 billion — 024, and is projected to grow to nearly $133 billion by 2029. The cryptocurrency-based iGami
• $39.8 billion — S. iGaming market is projected to reach $39.8 billion by 2029, growing at a compounded annual
• $25 billion — 9.8%, compared to projected revenue of $25 billion in 2024, according to Statista, driven
• $2.9 billion — s that India alone is expected to reach $2.9 billion in online gambling revenue by 2024, gro
• $4 billion — 024, growing at a 6% CAGR to just under $4 billion by 2029. Africa, with its expanding mob

Filing Documents

• ea0225176-s1a1_180life.htm (S-1/A) — 495KB
• ea022517601ex23-1_180life.htm (EX-23.1) — 4KB
• image_001.jpg (GRAPHIC) — 5KB
• 0001213900-24-111241.txt ( ) — 506KB

Risk Factors

Risk Factors 16 Incorporation by Reference 33 Cautionary Note Regarding Forward-Looking Statements 34

Use of Proceeds

Use of Proceeds 36 Dividend Policy 37 Beneficial Ownership of Securities 38 Selling Stockholder 39 Plan of Distribution 40

Description of Capital Stock

Description of Capital Stock 42 Legal Matters 46 Experts 46 Where You Can Find More Information 46 i Our logo and some of our trademarks and tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property of others. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus may appear without the ®, ™ and SM symbols. References to our trademarks, tradenames and service marks are not intended to indicate in any way that we will not assert to the fullest extent under applicable law our rights or the rights of the applicable licensors if any, nor that respective owners to other intellectual property rights will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. The market data and certain other statistical information used throughout this prospectus are based on independent industry publications, reports by market research firms or other independent sources that we believe to be reliable sources; however, we have not commissioned any of the market or survey data that is presented in this prospectus. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe these industry publications and third-party research, surveys and studies are reliable, provided that we have not commissioned any such information. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate t

View Full Filing

View this S-1/A filing on SEC EDGAR